
Jun 2, 2026
Rakovina’s Rx: AI and Austerity Fuel a Biotech Turnaround
Rakovina Therapeutics has successfully navigated a financial turnaround by integrating AI into its drug discovery process while implementing stringent cost controls.In its recent financial report for Q1 2026, Rakovina Therapeutics showcased a notable strategic shift, merging financial austerity with a robust investment in AI-driven drug discovery. This pivot has stabilized the company, improving its balance sheet and operational efficiency. The firm reported a 23% reduction in net loss, alongsid









